MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):439-445. doi: 10.15585/mmwr.mm6915a2.
In 1997, during the 41st session of the Regional Committee for the Eastern Mediterranean, the 21 countries in the World Health Organization (WHO) Eastern Mediterranean Region* (EMR) passed a resolution to eliminate measles (1). In 2015, this goal was included as a priority in the Eastern Mediterranean Vaccine Action Plan 2016-2020 (EMVAP) (2), endorsed at the 62nd session of the Regional Committee (3). To achieve this goal, the WHO Regional Office for the Eastern Mediterranean developed a four-pronged strategy: 1) achieve ≥95% vaccination coverage with the first dose of measles-containing vaccine (MCV1) among children in every district of each country through routine immunization services; 2) achieve ≥95% vaccination coverage with a second MCV dose (MCV2) in every district of each country either through implementation of a routine 2-dose vaccination schedule or through supplementary immunization activities (SIAs); 3) conduct high-quality, case-based surveillance in all countries; and 4) provide optimal measles clinical case management, including dietary supplementation with vitamin A (4). This report describes progress toward measles elimination in EMR during 2013-2019 and updates a previous report (5). Estimated MCV1 coverage increased from 79% in 2013 to 82% in 2018. MCV2 coverage increased from 59% in 2013 to 74% in 2018. In addition, during 2013-2019, approximately 326.4 million children received MCV during SIAs. Reported confirmed measles incidence increased from 33.5 per 1 million persons in 2013 to 91.2 in 2018, with large outbreaks occurring in Pakistan, Somalia, and Yemen; incidence decreased to 23.3 in 2019. In 2019, the rate of discarded nonmeasles cases was 5.4 per 100,000 population. To achieve measles elimination in the EMR, increased visibility of efforts to achieve the measles elimination goal is critically needed, as are sustained and predictable investments to increase MCV1 and MCV2 coverage, conduct high-quality SIAs, and reach populations at risk for not accessing immunization services or living in areas with civil strife.
1997 年,在第 41 届东地中海区域委员会会议期间,世界卫生组织(世卫组织)东地中海区域*(EMR)的 21 个国家通过了一项消除麻疹的决议(1)。2015 年,这一目标被列入 2016-2020 年东地中海区域疫苗行动计划(EMVAP)(2),并在第 62 届区域委员会会议上得到认可(3)。为实现这一目标,世卫组织东地中海区域办事处制定了四项策略:1)通过常规免疫服务,使每个国家的每个区的儿童均获得首剂含麻疹成分疫苗(MCV1)的接种率达到≥95%;2)通过实施常规 2 剂次免疫接种计划或开展补充免疫活动(SIAs),使每个国家的每个区的儿童均获得第二剂 MCV 的接种率达到≥95%;3)在所有国家开展高质量、基于病例的监测;4)提供最佳麻疹临床病例管理,包括膳食补充维生素 A(4)。本报告介绍了 2013-2019 年期间在东地中海区域消除麻疹的进展情况,并更新了之前的报告(5)。估计的 MCV1 接种率从 2013 年的 79%增加到 2018 年的 82%。MCV2 接种率从 2013 年的 59%增加到 2018 年的 74%。此外,在 2013-2019 年期间,大约有 3.264 亿儿童在补充免疫活动期间接种了 MCV。报告的确诊麻疹发病率从 2013 年的每百万人 33.5 例上升至 2018 年的每百万人 91.2 例,在巴基斯坦、索马里和也门发生了大规模疫情;发病率在 2019 年下降至 23.3。2019 年,每 10 万人中丢弃的非麻疹病例数为 5.4 例。要在东地中海区域消除麻疹,就迫切需要提高实现麻疹消除目标的可见度,还需要持续和可预测的投资,以提高 MCV1 和 MCV2 的接种率,开展高质量的补充免疫活动,并覆盖未获得免疫服务或生活在发生内乱地区的人群。